Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma

BACKGROUND: In recent years, programmed cell death protein-1 inhibitors, including sintilimab, have significantly prolonged the overall survival time of patients with unresectable or metastatic hepatocellular carcinoma (HCC); however, the cost-effectiveness of sintilimab is unclear. The aim of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Ting, Wang, Xintian, Cao, Yingdan, Yang, Lan, Wang, Zijing, Ma, Aixia, Li, Hongchao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673291/
https://www.ncbi.nlm.nih.gov/pubmed/36397064
http://dx.doi.org/10.1186/s12913-022-08661-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673291/
https://www.ncbi.nlm.nih.gov/pubmed/36397064
http://dx.doi.org/10.1186/s12913-022-08661-4

Ejemplares similares